The intervention showed no clear difference in BEV_RT (1 RCT; 75 participants) (low certainty).
mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
The review found no eligible studies for this question.
mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).
mTOR inhibitors showed no clear difference in haematological toxicities ‐ Anaemia compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors may leads to higher skin toxicities ‐ Mucositis compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors showed no clear difference in respiratory toxicity ‐ Interstitial pneumonitis compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors showed no clear difference in objective response rate: first‐line trial compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors showed no clear difference in objective response rate: second/third‐line trials compared with chemotherapy/hormone therapy (low certainty).
EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).
Oral showed no clear difference in mortality compared with intravenous antibiotic therapy (moderate certainty).
Oral showed no clear difference in treatment failure compared with intravenous antibiotic therapy (moderate certainty).
Oral showed no clear difference in treatment failure ‐ per protocol analysis compared with intravenous antibiotic therapy (moderate certainty).
Oral showed no clear difference in adverse events requiring discontinuation of antibiotics compared with intravenous antibiotic therapy (low certainty).
Oral showed no clear difference in treatment failure not dt modification in update compared with intravenous antibiotic therapy (moderate certainty).
It is very uncertain whether weekly paclitaxel changes overall survival compared with three‐weekly paclitaxel (very low certainty).